Based on the Wave Life Sciences Ltd stock forecast from 10 analysts, the average analyst target price for Wave Life Sciences Ltd is USD 19.56 over the next 12 months. Wave Life Sciences Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Wave Life Sciences Ltd is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, Wave Life Sciences Ltd’s stock price was USD 9.39. Wave Life Sciences Ltd’s stock price has changed by -6.57% over the past week, -11.91% over the past month and +38.50% over the last year.
No recent analyst target price found for Wave Life Sciences Ltd
No recent average analyst rating found for Wave Life Sciences Ltd
Company Overview Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. Read Less
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry i...Read More
Frequently Asked Questions About Wave Life Sciences Ltd (WVE) Stock
Based on ratings from 10 analysts Wave Life Sciences Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 15 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on WVE's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for WVE is USD 19.56 over the next 12 months. The maximum analyst target price is USD 36 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on WVE's stock to indicate if its overvalued.
The last closing price of WVE's stock was USD 9.39.
The most recent market capitalization for WVE is USD 1.73B.
Based on targets from 10 analysts, the average taret price for WVE is projected at USD 19.56 over the next 12 months.
This means that WVE's stock price may go up by +108.33% over the next 12 months.
We can't find any ETFs which contains Wave Life Sciences Ltd's stock.
As per our most recent records Wave Life Sciences Ltd has 266 Employees.
Wave Life Sciences Ltd's registered address is Marina One East Tower, Singapore, Singapore, 018936.
You can get more information about it from Wave Life Sciences Ltd's website at https://www.wavelifesciences.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Wave Life Sciences Ltd (WVE) Stock
Based on ratings from 10 analysts Wave Life Sciences Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 15 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on WVE's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for WVE is USD 19.56 over the next 12 months. The maximum analyst target price is USD 36 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on WVE's stock to indicate if its overvalued.
The last closing price of WVE's stock was USD 9.39.
The most recent market capitalization for WVE is USD 1.73B.
Based on targets from 10 analysts, the average taret price for WVE is projected at USD 19.56 over the next 12 months.
This means that WVE's stock price may go up by +108.33% over the next 12 months.
We can't find any ETFs which contains Wave Life Sciences Ltd's stock.
As per our most recent records Wave Life Sciences Ltd has 266 Employees.
Wave Life Sciences Ltd's registered address is Marina One East Tower, Singapore, Singapore, 018936.
You can get more information about it from Wave Life Sciences Ltd's website at https://www.wavelifesciences.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for WVE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
